Hot Investor Mandate: MedTech and Digital Health Focused VC Firm Seeks to Make New Investments In the US Over the Next 9-12 Months

25 Feb

A venture capital firm that manages just under $100 million in assets across 4 funds makes equity investments into companies ranging from a few hundred thousand dollars to $3 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 2-3 new investments over the next 9-12 months. The firm will invest in both seed and later stage companies. 

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. The firm is open to all sub-sectors and indications in the medical technology space except for those targeting diseases and disorders of the spine. 

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play an active role in the management. The firm is willing to invest in both public and privately held companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: VC Firm Invests in USA-Based Medical Device Companies Addressing Cardiovascular and Orthopedic Indications 

25 Feb

A VC firm is investing from its fifth fund that was closed in 2023. The firm focuses exclusively on early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities. 

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP. 

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

FDA’s Med Device Staff Firings: Industry Implications 

25 Feb

By Sougato Das, President and COO, Life Science Nation (LSN)

Sougato-DasThe FDA’s Center for Devices and Radiological Health (aka CDRH aka the folks who approve med devices) had firings a little more than a week ago, continuing from the layoffs at the NIH and CDC. Early signs indicate a reduction of 10% – 15%. Those who lost their jobs included those funded by medical device user fees and not tax-payer dollars. Since the cuts affected probationary employees the most, recent hires to evaluate newer technologies like AI-assisted imaging and digital health are gone, making it hard to imagine approvals for these modalities would not grind to a halt. AdvaMed’s head, Scott Whitaker, conveyed that AdvaMed had sent a letter to HHS in response, emphasizing the importance of AI and related technologies, the patient-facing effects throwing a wrench in the approval machine would have, and the lack of tax-payer savings. This may have been effective, as in breaking news today, the Associated Press reported that some of the fired individuals received calls and messages reversing their dismissals, stating terminations were “rescinded effective immediately.”

Besides staff cuts, there are other changes in FDA CDRH guidances, such as removal of requirements to have demographically diverse clinical trials. If the Trump administration continues to lower the regulatory hurdles required for approval, approval times could accelerate despite reduced staff, assuming further layoffs do not materialize and funds from user fees are made available again. Of course, this could result in products with less safety testing, which could lead to recalls and trust erosion.

The million-dollar (well, actually billion dollar) question is: how will these changes affect seed and series A-B funding for med tech, health tech and AI? Usually, regulatory uncertainty has a dampening effect on the investment climate. Companies may need to hedge their bets by doubling down on fundraising and partnering activity. How many meetings have you had in the last 3 months? How many leads do you have? How many meetings do you need to close your next fundraise? LSN can help you dramatically accelerate your business development. With the largest and most detailed life science investor/in-licensor database and the largest investment conferences (by number of attending investors) in the world, LSN is poised to help get you funded before any potential downturn. Reach us at: resi@lifesciencenation.com

Exploring the Future of Biotech Investment: The Therapeutics Panel at RESI Europe 

25 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With biotech venture capital investment surging by over 33% in 2024 and in-licensing activity remaining strong, optimism is growing in the life science ecosystem. The Therapeutics panel at RESI Europe in Barcelona, taking place at the InterContinental Hotel on April 1, will bring together key investors to explore the evolving landscape of biotech investment and partnerships.

This panel will examine emerging trends and therapeutic breakthroughs, providing insight into the indications and modalities attracting investor interest. Discussions will also highlight the role of venture capital and in-licensing partners in driving innovation, as well as key considerations for biotech companies navigating R&D and scaling operations. Given the high-risk nature of early-stage biotech investment, panelists will share perspectives on how to de-risk opportunities through due diligence and strategic partnerships.

Moderated by Jim McGough of Mid Atlantic Bio Angels, this discussion will feature an esteemed lineup of investor panelists, including Laura Rodriguez of Invivo Partners, Carla Benichou of RV Invest GmbH, and Artemy Shumsky of LongeVC. Their collective expertise will offer a comprehensive look at how investment and collaboration are shaping the future of biotech innovation.

Jim-McGough
Jim McGough
Managing Partner
Mid Atlantic Bio Angels
(Moderator)		 Carla-Benichou
Carla Benichou
Senior Investment Analyst
RV Invest GmbH
Laura-Rodriguez
Laura Rodriguez
Partner
Invivo Partners		 Artemy-Shumskiy
Artemy Shumskiy
Senior Associate
LongeVC

Investment and strategic partnering remain essential in advancing therapeutics that address high unmet medical needs. Whether you are a biotech entrepreneur seeking funding or an investor looking to stay ahead of industry trends, this panel promises valuable insights into the dynamic world of biotech investment.

Join us at RESI Europe to gain firsthand knowledge from top investors and forge meaningful connections that could help propel the next wave of groundbreaking therapies to market.

Hot Investor Mandate: Investment Firm Managing Multi-Billion AUM Invests Up to $25M in Therapeutics and Medial Device Companies Across the Globe

19 Feb

A global investment firm focuses on private venture and growth assets. The firm manages over USD 2 billion and invests in highly innovative and disruptive companies in the biotechnology, enterprise-facing core technology, and consumer sectors. The firm is open to global companies in Pre-Seed to Series B rounds and prefers to lead its investments. The firm is capable of investing up to $25M USD. 
 
Within life sciences, the firm invests in therapeutics and med-techs with strong preference in aging-related indications including, but not limited to, oncology, immunology, neurology, ophthalmology, cardiovascular, liver, and kidney diseases. The firm typically avoids rare diseases as the firm emphasizes breakthrough technologies. The firm is open to company being as early as discovery stages. 
 
The firm prefers to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based VC Firm Invests in All Life Science Sectors Across Seed to Series B Rounds, Most Interested in Innovative Medical Devices

19 Feb

A venture capital firm based in the US actively invests and provides support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 60 companies and continues to actively seek life science investments with its third fund, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China. 
 
The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment. 
 
The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: VC Firm With US & Middle East Offices Invests Up to $15M in Life Science Technologies, With Focus on Longevity

19 Feb

A boutique venture capital firm with offices in US and the Middle East has invested alongside Tier 1 VCs in several companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies. 
 
The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity.  

 
The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

← Older Entries
Newer Entries →